La catena delle opzioni mostra i dati chiave delle opzioni azionarie di  a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ..

 (PETQ) Azioni, Catena delle Opzioni

PetIQ

PETIQ INC COM CL A

Needham analyst James Ricchiuti maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $31.

News

Price Target

Analyst Ratings

KRNT

Needham Maintains Buy on Kornit Digital, Raises Price Target to $31

B of A Securities analyst Julien Dumoulin-Smith maintains TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) with a Buy and lowers the price target from $7 to $4.

TPIC

B of A Securities Maintains Buy on TPI Composites, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

Reiteration

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

B of A Securities analyst Dimple Gosa maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and lowers the price target from $65 to $52.

B of A Securities Maintains Buy on NEXTracker, Lowers Price Target to $52

B of A Securities analyst Julien Dumoulin-Smith maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Buy and lowers the price target from $25 to $24.

FLNC

B of A Securities Maintains Buy on Fluence Energy, Lowers Price Target to $24

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and raises the price target from $17 to $21.

CLBT

Needham Maintains Buy on Cellebrite DI, Raises Price Target to $21

B of A Securities analyst Julien Dumoulin-Smith maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Underperform and lowers the price target from $72 to $62.

ENPH

B of A Securities Maintains Underperform on Enphase Energy, Lowers Price Target to $62

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Hold.

FOLD

Needham Reiterates Hold on Amicus Therapeutics

B of A Securities analyst Julien Dumoulin-Smith maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Underperform and lowers the price target from $8 to $7.

B of A Securities Maintains Underperform on Bloom Energy, Lowers Price Target to $7

Piper Sandler analyst Patrick Moley reiterates MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Neutral and maintains $265 price target.

MKTX

Piper Sandler Reiterates Neutral on MarketAxess Holdings, Maintains $265 Price Target

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Hold.

SRDX

Needham Reiterates Hold on Surmodics

Amazon Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy has expressed his disdain for bureaucracy and announced plans to reduce managerial layers within the company
What Happened: In a company-wide meeting on Tuesday, Jassy outlined the company&#8217;s decision to cut down on&nbsp;the number of managers.
The&nbsp;move was aimed at speeding up decision-making processes and preserving Amazon&#8217;s unique culture, which Jassy believes is being stifled by excessive management layers, <a href="https://www.businessinsider.in/tech/news/in-an-all-hands-meeting-amazon-ceo-andy-jassy-tells-employees-why-he-wants-fewer-managers-i-hate-bureaucracy/articleshow/114996847.cms">reported</a> Business Insider, citing a recording of the meeting.
&#8220;The goal again is to&nbsp;allow us to have higher&nbsp;ownership and to move more&nbsp;quickly,&#8221; Jassy stated during the meeting.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
Amazon announced in September that it plans to increase the ratio of individual workers to managers by 15% by the end of the first quarter of 2025.
As part of this initiative, Amazon launched a &#8220;Bureaucracy&nbsp;Mailbox&#8221; last month, where employees&nbsp;can voice concerns about unnecessary processes or rules.
 Jassy revealed that over 150 suggestions received through this platform have already been acted upon.
&#8220;The reality is that the&nbsp;S team and I hate&nbsp;bureaucracy,&#8221; Jassy said, referring to&nbsp;Amazon&#8217;s&nbsp;senior leadership team. &#8220;One of the reasons I&#8217;m still at&nbsp;this company is because it&#8217;s&nbsp;not a political or bureaucratic&nbsp;place.&#8221;
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: For the third quarter of 2024, Amazon reported <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">net sales of $158.9 billion</a>, up 11% year-over-year, beating Street consensus estimates.
Operating income for the third quarter reached $17.4 billion, an increase from $11.2 billion in the same period last year. Amazon Web Services, or AWS, was the primary driver, contributing $10.4 billion in operating income, compared to $7 billion in the third quarter of the previous year.
Amazon has also been expanding its <a href="https://www.benzinga.com/markets/equities/24/11/41735903/meta-amazon-microsoft-partner-on-defense-ai-initiative">partnerships and initiatives</a>, including a collaboration with Meta Platforms Inc., Microsoft Corp., and others on a defense AI initiative.
However, the company has also faced internal challenges. Last month, AWS CEO Matt Garman defended the company's <a href="https://www.benzinga.com/news/24/10/41394784/amazon-aws-ceo-stands-firm-on-5-day-office-policy-opponents-can-head-for-the-exit-door-there-are-oth">contentious new five-day in-office policy</a>, suggesting that those who oppose it may consider other employment options.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41706934/how-to-master-ios-18s-control-center-tips-to-reset-and-customize-your-iphones-quick-access-hub?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Master iOS 18&#8217;s Control Center: Tips To Reset And Customize Your iPhone&#8217;s Quick Access Hub</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

Tech

Media

AMZN

Amazon's Andy Jassy Says 'I Hate Bureaucracy' As He Plans To Slash Managerial Layers: 'The Goal Again Is… To Move More Quickly'

Needham analyst James Ricchiuti reiterates iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) with a Hold.

IRBT

Needham Reiterates Hold on iRobot

Needham analyst Ryan Koontz reiterates Kaltura (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>) with a Buy and maintains $3 price target.

KLTR

Needham Reiterates Buy on Kaltura, Maintains $3 Price Target

Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $151 price target.

PRAX

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $151 Price Target

Needham analyst Bernie McTernan maintains Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Buy and raises the price target from $6 to $7.

SGHC

Needham Maintains Buy on Super Group (SGHC), Raises Price Target to $7

Commodities

Contracts

Markets

General

FLNG

Flex LNG Has Agreed With The Charterer Of Flex Courageous And Flex Resolute, A Supermajor, To Amend The Existing Time Charter Agreements For Two LNG Carriers Where The Parties Have Agreed A New Firm Period From 2029 To 2032 Which May Be Extended By An Additional Seven Years In Total Until 2039

Oculis Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) reported quarterly losses of CHF(0.48) per share which beat the analyst consensus estimate of CHF(0.49) by 2.04 percent.

Earnings

Earnings Beats

Oculis Holding Q3 2024 Adj. EPS CHF(0.48) Beats CHF(0.49) Estimate, Cash Balance Of CHF105.5M

Piper Sandler analyst Brent Bracelin downgrades HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) from Overweight to Neutral and raises the price target from $570 to $640.

Downgrades

HUBS

Piper Sandler Downgrades HubSpot to Neutral, Raises Price Target to $640

Piper Sandler analyst Brent Bracelin maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Overweight and raises the price target from $13 to $18.

FRSH

Piper Sandler Maintains Overweight on Freshworks, Raises Price Target to $18

Lake Street analyst Ryan Meyers maintained a Buy rating on Petiq (PETQ – Research Report) today and set a price target of $28.00. The company's sha...

Lake Street Remains a Buy on Petiq (PETQ)

PetIQ Non-GAAP EPS of $0.70, revenue of $328.9M

PetIQ: Attractive Acquisition Offer After Strong Earnings Growth In Q2

The pet care industry is expected to witness immense growth owing to a surge in pet adoptions, veterinary innovations, and rising disposable income. Thus, one could scoop up shares of fundamentally solid pet-care stocks with tail-wagging potential, like Zoetis (ZTS), Chewy (CHWY), and PetIQ (PETQ). Read more… The pet care industry is witnessing remarkable growth driven by a surge in global pet adoptions and significant advancements in veterinary care. Concurrently, the increased investment by pet owners in care and accessories is expected to bolster strong growth prospects for the sector.
Given this backdrop, investors could consider loading up on shares of fundamentally sound pet care stocks Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>), Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>), and  PetIQ, Inc. (<a href="https://stocknews.com/stock/PETQ/">PETQ</a>) that seem well positioned to capitalize on the industry tailwinds.
In recent times, pet adoption has increased drastically, and the trend continues. A substantial number of American households own a pet, with dogs being the most popular. <a href="https://www.forbes.com/advisor/pet-insurance/pet-adoption-statistics/">Pet ownership</a> is increasing particularly amongst young generations, with millennials having the highest share of pet owners at 33%.
Advancements in technology are also transforming veterinary medicine, leading to improved diagnostic capabilities, innovative treatment options, and enhanced medical devices. Innovations like telemedicine, digital imaging, minimally invasive surgeries, and advanced laboratory diagnostics have significantly upgraded the quality of animal care and broadened the scope of veterinary services.
According to a Grand View Research study, the U.S. veterinary medicine market is expected to grow at <a href="https://www.grandviewresearch.com/industry-analysis/us-veterinary-medicine-market-report">a CAGR of 6.8%</a> from 2024 to 2030. This growth is projected to push the market to a substantial $21.80 billion, reflecting the increasing demand for advanced veterinary care.
Moreover, an increase in disposable income has further fueled higher pet ownership rates, prompting greater investment in pet care products like accessories, health items, and fashion. According to the Bureau of Economic Analysis data, disposable personal income <a href="https://www.bea.gov/news/2024/personal-income-and-outlays-july-2024">rose by $54.8 billion</a> or 0.3% in July 2024.
Looking forward, as per a report by Mordor Intelligence, the pet care market is expected to reach $24.59 billion by 2029, expanding at a <a href="https://www.mordorintelligence.com/industry-reports/pet-care-market">CAGR of 4.2%</a>.
Given these positive trends, let's discuss the fundamentals of three pet-care stocks, starting with #3.
Stock #3: Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>)
ZTS develops, manufactures, and commercializes medicines, vaccines, and diagnostic products and services for animal health. It operates in eight core species and seven major product categories, with products sold in 45 countries and over 100 countries. The company operates through two segments: United States and International.
On April 28, ZTS <a href="https://investor.zoetis.com/news/news-details/2024/Zoetis-to-Sell-Medicated-Feed-Additive-Portfolio-to-Phibro-Animal-Health/default.aspx">announced its definitive agreement</a> with Phibro Animal Health Corporation (<a href="https://stocknews.com/stock/PAHC/">PAHC</a>), a global leader in animal health and nutrition. As part of this deal, PAHC will acquire ZTS' medicated feed additive (MFA) product portfolio, select water-soluble products, and related assets for around $350 million.
The transaction would allow ZTS to streamline its focus on core areas while unlocking capital for strategic growth opportunities.
For the fiscal 2024 second quarter that ended on June 30, 2024, ZTS' revenue increased 8.3% year-over-year to $2.36 billion. Its non-GAAP gross profit grew 7.4% from the year-ago value to $1.69 million.
In addition, non-GAAP net income attributable to ZTS came in at $711 million or $1.56 per share, indicating a year-over-year growth of 9% and 10.6%, respectively.
Analysts expect ZTS' revenue for the fiscal third quarter (ending September 2024) to increase 6.4% year-over-year to $2.29 billion. Meanwhile, its EPS for the same quarter is expected to grow 7.7% from the prior year's period to $1.46. Furthermore, the company surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of ZTS have surged 3.7% in the past month and 9% in the past three months to close the last trading session at $187.33.
ZTS' bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ZTS has a B grade for Quality and Stability. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry, the stock is ranked #39 out of 158 stocks.
<a href="https://stocknews.com/stock/ZTS/">Click here</a> to access additional ZTS ratings for Sentiment, Momentum, Growth, and Value.
Stock #2: Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>)
CHWY operates as a pure-play e-commerce business. It offers pet food, treats, supplies, and medications, along with other pet health products. The company also provides pet services for dogs, cats, fish, birds, small pets, horses, and reptiles. These are available through its retail websites and mobile applications.
For the fiscal 2024 second quarter ended on July 28, 2024, CHWY's <a href="https://www.investopedia.com/terms/n/netsales.asp">net sales</a> increased 2.6% year-over-year to $2.86 billion. Its gross profit rose 7% from the year-ago value to $843.84 million. Additionally, the company's adjusted EBITDA of $144.84 million indicates an increase of 64.3% from the prior year's quarter.
Furthermore, the company's adjusted net income and adjusted EPS came in at $104.79 million and $0.24, up 62.3% and 60% from the previous year's period, respectively.
For the fiscal 2025 third quarter ending October 2024, CHWY's revenue and EPS are expected to increase 4.2% and 49.9% year-over-year to $2.85 billion and $0.22, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters, which is impressive.
Shares of CHWY have gained 22.1% over the past three months and 53.3% over the past six months to close the trading session at $27.15.
CHWY's sound fundamentals are mirrored in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CHWY has an A grade for Growth and a B grade for Quality and Sentiment.
Within the A-rated <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry, CHWY is ranked #15 among the 52 stocks.
In addition to the POWR Ratings we've stated above, we also have CHWY's ratings for Stability, Value, and Momentum. Get all CHWY ratings <a href="https://stocknews.com/stock/CHWY/">here</a>.
Stock #1: PetIQ, Inc. (<a href="https://stocknews.com/stock/PETQ/">PETQ</a>)
PETQ is a pet medication and wellness company that offers veterinary products and services. The company's Products segment distributes value-branded and third-party products for dogs and cats. Meanwhile, the Services segment offers diagnostic tests, vaccinations, and specialty medications.
On August 7, PETQ <a href="https://ir.petiq.com/news-releases/news-release-details/petiq-inc-enters-definitive-agreement-be-acquired-bansk-group">announced its acquisition</a> by Bansk Group, a consumer-focused private investment firm. Bansk will acquire all outstanding shares of PETQ's common stock at $31.00 per share, valuing the transaction at approximately $1.5 billion.
Cord Christensen, Founder, Chairman, and CEO of PETQ, stated that the Board considers this transaction a positive outcome for both the company and its stockholders.
On March 14, PETQ announced the <a href="https://ir.petiq.com/news-releases/news-release-details/petiq-inc-celebrates-expansion-mintiesr-dental-treats-brand">launch of its new product</a>, Minties&#xAE; dental treats, designed for tiny/small, medium, and large-sized dogs, as well as cats. By continuously innovating and introducing new products to the pet-care market, the company is positioned to increase its popularity and expand its customer base.
PETQ's total net sales increased 4.6% year-over-year to $328.94 million for the fiscal 2024 second quarter, which ended on July 30. Its gross profit rose 19.5% from the year-ago value to $88.28 million.
Moreover, the company's operating income came in at $25.58 million, increasing 36.7% from the prior year's quarter. Plus, its adjusted EBITDA was reported to be $39.04 million, indicating an increase of 18.8% year-over-year.
In addition, the company's adjusted net income came in at $24.42 million or $0.70 per share, up 82.2% and 52.2% from the prior year's quarter, respectively.
The consensus revenue and EPS estimates of $1.16 billion and $1.56 for the fiscal year ending December 2024 exhibit a year-over-year rise of 4.9% and 25.6%, respectively. Moreover, the company has topped the consensus EPS estimates in all the four trailing quarters.
Shares of PETQ have gained 47.8% over the past three months and 81.8% over the past six months to close the trading session at $30.52.
PETQ's solid fundamentals are echoed in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
PETQ has an A grade for Growth and a B for Value. It is ranked #19 out of 62 stocks in the <a href="https://stocknews.com/category/medical-services/">Medical - Services</a> industry.
Beyond what is stated above, we've also rated PETQ for Sentiment, Stability, Momentum, and Quality. Get all PETQ ratings <a href="https://stocknews.com/stock/PETQ/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
ZTS shares were unchanged in premarket trading Thursday. Year-to-date, ZTS has declined -4.37%, versus a 16.65% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/zts-chwy-petq-pahc-3-pet-care-stocks-with-tail-wagging-potential/>3 Pet Care Stocks With Tail-Wagging Potential</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pet Care Stocks With Tail-Wagging Potential

Catalyst Watch: FOMC, FedEx earnings, Electronic Arts event, and triple witching day

The latest announcement is out from Petiq ( ($PETQ) ). PetIQ, Inc., a leading pet health and wellness company, has secured shareholder approval for...

PetIQ Merges with Bansk Group in $1.5B Deal

PetIQ (PETQ) announced that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to app...

PetIQ stockholders vote to approve merger agreement to be acquired by Bansk

White Brook Capital Partners Q3 2024 Commentary

PetIQ (PETQ) announced the completion of its acquisition by Bansk Group in an all-cash transaction valued at approximately $1.5 billion. PetIQ stoc...

PetIQ announces completion of acquisition by Bansk Group

Petiq ( ($PETQ) ) has provided an update. PetIQ, Inc. has successfully completed its acquisition by Bansk Group for approximately $1.5 billion in a...

PetIQ Acquired by Bansk Group, Delisted from Nasdaq

AFYA

ALAB

ALTM

ASTS

BCDA

BIRK

BLDP

BLDR

BYDDF

CART

CHWY

CRWD

CSCO

CYBN

DECK

DNUT

ELTP

EXPD

FCEL

FERG

FFIE

FSLR

GPRE

LSTR

MSFT

NVDA

OKTA

PAHC

PETQ

PLCE

PLUG

QCOM

RBLX

RDDT

SEDG

SHAK

STLA

TMUS

TSLA

USAU

VTLE

WDAY

ZVRA

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PETQ, ESGR, GVP, SQSP on Behalf of Shareholders

PETQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of PetIQ, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, PETQ, IP, SQSP on Behalf of Shareholders

Legal

Kuehn Law Encourages MNTX, FYBR, EVBN, and PETQ Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PETQ, BTTR, GATO on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, PETQ, FBMS on Behalf of Shareholders

Kuehn Law Encourages FBMS, WSBC, OB, and PETQ Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PETQ, FBMS, WSBC, OB on Behalf of Shareholders

Comments

(PETQ) Opzioni

(PETQ) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO